Loading data for NVCR — first visit, this takes a few seconds.
NovoCure Limited
15.51 +0.16 (1.04%)
- Рыночная капитализация
- $1.82B
- Объём торгов
- 1.13M
- Следующая дата отчётности
- Oct 29, 2026
NovoCure Limited (NVCR): цена акции, анализ и данные
Внутренняя стоимость
Прогноз аналитиков
Прогнозы по акции →Последние результаты
| Отчитано | К прогнозу | Изменение г/г | |
|---|---|---|---|
| Выручка | $183.6M | n/a | +15.60% |
| EPS | -$0,13 | +$0,20 | +63.89% |
Метрики
- Бид
- 11.31
- Рыночная капитализация
- 1.82B
- Выручка (TTM)
- 699M
- Чистая прибыль (TTM)
- -149M
- 1.01
- -1.3
- n/a
- -19.15
- P/B (TTM)
- 5.38
- P/S (TTM)
- 2.60
- Дата отчёта
- Oct 29, 2026
- Аск
- 19.91
- Объём торгов
- 1,127,182
- Ср. объём (20д)
- 1,586,812
- Открытие
- 15.50
- Пред. закрытие
- 15.35
- Диапазон дня
- 15.35 - 16.00
- Диапазон за 52 недели
- 9.82 - 21.45
- Аналитики
- n/a
- Целевая цена
- n/a
- Дивиденды
- n/a
- Дата отсечки
- n/a
О компании NovoCure Limited
Профиль →NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Отрасль Medical Devices
Сектор Healthcare
Дата IPO Oct 1, 2015
Сотрудники 1,605
Биржа NasdaqGS
Тикер NVCR